Anti-CD38 Binding Domains for Multiple Myeloma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-CD38 antibodies have limitations in effectively treating CD38-expressing tumors, which often result in a poor prognosis for cancer patients.
Innovation Solution
Development of a novel anti-CD38 antigen binding domain with specific amino acid sequences for the variable heavy and light domains, which can bind to human and cynomolgus CD38 with high affinity, even in the presence of existing antibodies like daratumumab.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-CD38 antibodies are used for treatment, then existing therapeutic approaches can be maintained, but treatment effectiveness is insufficient leading to poor prognosis
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences of the antibody variable regions (VH and VL domains) to create novel binding domains with improved characteristics. Specifically, the invention defines precise CDR sequences (vhCDR1-3 and vlCDR1-3) that differ from existing antibodies, thereby changing the molecular parameters to achieve enhanced binding affinity and therapeutic effectiveness against CD38-expressing tumors.
2Strength
If existing anti-CD38 antibodies are used, then current treatment protocols can be maintained, but binding affinity and therapeutic capability are limited
Solution Approach 1:
The patent applies segmentation by focusing on and optimizing specific segments of the antibody molecule - namely the complementarity-determining regions (CDRs) within the variable heavy and light domains. Rather than redesigning the entire antibody structure, the invention segments the problem into specific CDR sequences (vhCDR1, vhCDR2, vhCDR3, vlCDR1, vlCDR2, vlCDR3) that can be independently defined and optimized to achieve high binding affinity while maintaining overall antibody structure.
Data Source
AI summary
Provided in this disclosure are anti-CD38 binding domains, a composition comprising the anti-CD38 binding domains, nucleic acids encoding the anti-CD38 binding domains, and a method of using the anti-CD38 binding domains or the composition for treating multiple myeloma.